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Abstract
Background: Despite a worldwide common and progressive nature of benign prostate hyperplasia (BPH) in older
men, no association has been observed between a causative pathogen and other etiology so far.
Methods: In this study, we investigated a causative association of Trichomonas vaginalis, a flagellate protozoan
parasite, in 171 BPH cases presenting without symptoms of prostatitis at a surgical outpatient clinic in Kuwait. We
detected T. vaginalis DNA by polymerase chain reaction (PCR) and T. vaginalis antigen by immunocytochemistry
(ICC) in the prostate tissue of these cases. A total of 171 age-matched controls with no urinary tract symptoms
were also included in the study. A detailed information regarding the sexual history and sexually transmitted
infections (STIs) was enquired from all the enrolled subjects.
Results: We detected T. vaginalis DNA and T. vaginalis antigen in 42 (24.6 %) and 37 (21.6 %) of the 171 BPH cases
respectively in their prostate tissue. Both these assays showed a very good agreement and statistically no significant
difference in their sensitivities and specificities. A relatively higher seropositivity rate for antibodies to T. vaginalis
was detected in BPH cases (53 of 171 cases, 31.0 %) than in the control group (26.9 %) [p: 0.19] and both were
higher than in earlier reports but no significant association was observed between BPH and T. vaginalis serostatus.
However, a greater proportion of seroreactive BPH cases had high IgG2 antibody absorbance score than in the
control group (p:0.000). Furthermore, no significant association was observed between T. vaginalis seropositivity and
presence of T. vaginalis DNA in the prostate tissue.
Conclusions: Our study documents T. vaginalis DNA and T. vaginalis antigen in 24.6 and 21.6 % respectively in the
prostate tissue of the BPH cases. We also detected a relatively higher seropositivity rate for antibodies to T. vaginalis
both in the BPH cases and in normal control group, 31 and 26.9 % respectively but no significant association was
observed between BPH and T. vaginalis serostatus or presence of T. vaginalis DNA in the prostate tissue. Further
epidemiological and case-controlled studies are needed to focus on local response to chronic asymptomatic
retention of T. vaginalis in prostate tissue in the development of benign prostate hyperplasia.
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Background
Benign prostatic hyperplasia (BPH) and prostate cancer
(PCa) represent the most common urologic diseases among
the elderly males resulting in more than 2 million visits per
year; 8 % of the total urologic visits and 1 % of family phys-
ician visits in the USA [1–3]. Its prevalence among men at
risk is believed to be between 5 and 8 % [4, 5]. BPH and
PCa are considered chronic diseases, with early initiation
and slow progression. Despite extensive research, the
pathophysiology of BPH and PCa is not yet completely
understood however, several observational and case-control
studies have documented the role of sexually transmitted
infections (STIs) in chronic inflammation as an important
factor in BPH development and progression [6–8]. Several
sexually transmitted agents such as Neisseria gonorrhoeae,
Chlamydia trachomatis and Trichomonas vaginalis (T.
vaginalis) are known to cause chronic inflammation within
the prostate gland’s tissue [9]. However, a recent large retro-
spective and prospective study did not support associations
of several known STIs with BPH with the exception of T.
vaginalis infection that showed modest association with
BPH [10]. T. vaginalis is a common parasitic sexually trans-
mitted infection, with an estimated 174 million annual in-
fections globally. Studies have shown that T. vaginalis can
be associated with asymptomatic infections in 50–75 % of
infected men and a number of observations support an as-
sociation between T. vaginalis and prostatitis [11, 12]. As
such, chronic prostatic infection with T. vaginalis may initi-
ate an inflammatory response that could increase the risk
of developing BPH and PCa. The objective of the present
study was to investigate the potential association between
T. vaginalis infection and BPH by detecting T. vaginalis
DNA and antigen in the prostate tissue and T. vaginalis




A total of 177 BPH cases aged >60 years of age without
clinical symptoms of prostatitis reporting at the Urological
Clinic, Mubarak Al-Kabir Teaching Hospital, Kuwait were
registered and treated for BPH by transurethral resection
of the prostate (TURP) during the period June 2013-
December 2014. All enrolled cases were given a code
number to preserve their confidentiality. From each of the
enrolled cases, 5–6 small biopsy specimens were taken
from the prostate for histopathology routine examination
to confirm the diagnosis of BPH and 5 ml. blood to assess
T. vaginalis serostatus. The biopsy specimens were also
processed to detect T. vaginalis DNA and antigen in the
tissue. The tissue was also processed to detect other rele-
vant bacterial and viral pathogens by multiplex PCR and
culture. A detailed information regarding the sexual his-
tory and sexually transmitted infections (STIs) was
enquired from all the enrolled subjects. When available,
their hospital records were also screened for this
information.
We also included 177 control subjects from the same
population group who had provided blood at the out-
patient clinic for conditions other than prostate and/or
urinary tract infection. For statistical efficiency, control
subjects were individually matched to BPH cases by age.
Polymerase chain reaction (PCR) for detection of T.
vaginalis DNA in prostate tissue
For detection of T. vaginalis, the prostate tissue was proc-
essed and the DNA extracted as described earlier [13, 14].
Briefly, the tissue samples were cultured in TYI S 33
medium with 10 % bovine serum albumin at 37 °C for
four days under anerobic conditions. The presence of T.
vaginalis parasite was confirmed by light microscopy of
the pellet after centrifugation of the culture supernatant.
T. vaginalis-specific PCR was performed directly on the
prostate tissue specimens and the DNA was extracted
using QIAamp DNA Mini kit (Qiagen) following manu-
facturer’s instructions. A set of primers targeting a con-
served region of the beta-tubulin genes of T. vaginalis
(btub1-2, and −3) was used for amplification; for BTUB 9:
5′ CAT TGATAA CGA AGC TCT TTA CGAT 3′ (posi-
tions 850–874), and for BTUB 2: 5′ GCA TGT TGT
GCC GGA CAT AAC CAT 3′ (positions 961–938) [13,
14]. The performance of beta-tubulin primers BTUB9 and
BTUB2 was earlier evaluated in a pilot study to screen
pregnant women for STDs including T. vaginalis at the
maternity clinic in Kuwait during 2012–2013 using a
series of positive controls.
A positive (ATCC 30236) and a negative (distilled water)
control was used with each run. The DNA was amplified
by PCR using an automated thermocycler (Perkin-Elmer
Cetus, Norwalk, Conn.) using the standard final PCR reac-
tion mixture (50 μl). A single predicted 112 bp PCR prod-
uct was visualized on a 2 % agarose gel stained with
ethidium bromide. All PCR positives were confirmed by
sequence analysis of the BTUB PCR product using a
3100-Avant Genetic analyzer (Applied Biosciences) and
comparing data with Genebank as reported earlier [14].
Immunocytochemistry (ICC) of fixed prostate tissue to
detect Trichomonas vaginalis parasite antigen (TV Ag)
The fresh biopsies were fixed in formalin, processed and
embedded in paraffin wax and a 4–5 μm sections were cut.
Staining was done after deparaffinization and rehydration
by graded alcohols. Endogenous peroxidase activity was
blocked using 0.3 % hydrogen peroxide in Tris-buffered sa-
line. For antigen retrieval the sections were treated with
10 mmol/l citrate buffer (pH 6.1) in microwave for 5 min
and then incubated with the mouse primary monoclonal
anti-Trichomonas vaginalis antibody (MYBioSource, San
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Diego, USA). Avidin-biotin complex (ABC) method was
used for antigens visualization. Briefly, EnVision Flex Dual
Link horseradish peroxidase/DAB visualization system
(Dako) was used and counterstained with haematoxylin.
The specimen was considered positive if either nuclear only
staining or nuclear and cytoplasmic staining was present.
Positive control slides with Trichomonas vaginalis parasites
were used for each run of samples.
Detection of T. vaginalis serostatus
T. vaginalis antibody serostatus (IgG, IgG subtypes) was
measured by using an in-house indirect ELISA that detects
antibodies against purified, recombinant α-actinin protein
from T. vaginalis parasite (strain C-1:NIH) as described
earlier [15] with slight modifications. Briefly, the recombin-
ant α-actinin protein was purified from the harvested
Escherichia coli colony containing the recombinant plasmid
wit α-actinin gene. Optimum dilution of the recombinant
protein, serum and antihuman conjugates used in ELISA to
screen for serostatus were determined by a checker-board
titration. A panel of five known positive specimens from
confirmed T. vaginalis cases and negative pooled specimens
from uninfected individuals were used in random order
with each run of the assay to determine absorbance score.
Briefly, 100 μl of paired plasma samples from the cases and
controls diluted at 1:200 in phosphate-buffered-saline-
Tween 20 containing 5 % skim milk was added into micro-
titer wells coated with recombinant α-actinin protein over-
night. All specimen were used in duplicate in optimum
dilutions as determined above (IgG; 1:200, IgG subtypes;
1:40) and inferences were based on the mean of duplicate
values. The horseradish peroxidase-labelled antihuman IgG
and the biotin-labelled antihuman IgG1/IgG2/IgG3/IgG4
(Sigma, St. Louis, MO, USA) were used at the calculated
optimum dilution in PBS—Tween 20—BSA. The working
dilution of HRP-labelled antihuman IgG was determined at
1:5000 and for IgG1/IgG2/IgG3/IgG4 at 1:1000, 1:5000,
1:2500 and 1:5000, respectively. The plates were incubated
for 1 h at 37 °C for 30 min followed by incubation with the
substrate H2O2-OPD in citrate buffer. The reaction as
stopped with H2SO4. The cut-off points for seropositivity
were determined by obtaining positive to negative (P/N) ra-
tios of the mean of duplicate optical densities (ODs) ± 2
standard deviations (SD) values of the positive and negative
control specimens as described earlier [15, 16]. The absorb-
ance score was then determined by comparing the P/N
values with ODs of the known positive control specimens.
Samples with absorbance score of 1 with mean OD value
of >0.70 were considered positive for T. vaginalis infection.
Ethics statement
The present study was reviewed and approved by the Fac-
ulty of Medicine, Kuwait University and Kuwait Institute
for Medical Specialization (KIMS) joint Research Ethics
Committee. The Committee reviews experimental proto-
cols involving human subjects and/or animal as per inter-
national standardized ethical guidelines. All patients gave
their informed consent to their prostate tissue and blood
sample for testing and they were informed of their study-
related test results.
Statistical analysis
Statistical analysis were performed using SPSS 12.0.1 (SPSS
Inc.). We used One way ANOVA and Post Hoc tests to
analyze variables (total prostate specific antigen and anti-
body absorbance means, medians and proportions) by t test
using independent samples. The comparative performance
of T. vaginalis antigen test and PCR assay was done by
McNemar test. To explore potential associations of T. vagi-
nalis serostatus and BPH, we used conditional logistic re-
gression to analyze potential BPH risk according to T.
vaginalis antibody serostatus. Odds raios (ORs) and 95 %
confidence intervals (CIs) were estimated by comparing
average optical density values and positive/negative values
of T. vaginalis seropositive and -negative cases. Differences
were considered significant with p <0.05.
Results
The prostate tissue from all 177 BPH cases was processed
for PCR analysis using a set of BTUB 9/2 primer set tar-
geting a well-conserved region in the beta-tubulin genes
of T. vaginalis (btub1-2, and −3) which amplified a single
predicted 112 bp PCR product visualized on gel electro-
phoresis. We detected T. vaginalis DNA by PCR in 43 of
177 (24.3 %) cases. Six of the BPH cases who had charac-
teristic BPH findings on routine histological examination
were also shown to have additional incidental prostate
cancer (iCaP), of which one was also positive for T. vagi-
nalis DNA. The iCaP cases were removed from further
testing and statistical analysis. Thus, T. vaginalis DNA
was detected in 42 of 171 (24.6 %) BPH cases in prostate
tissue specimens by PCR (Table 1). All PCR positives were
confirmed by sequence analysis of the BTUB PCR product
using a 3100-Avant Genetic analyzer and showed highest
similarity to Btub1 (data not shown). The mean age of
BPH cases positive for T. vaginalis DNA was 65. 6 years
(SD = ±5.3 years) and the DNA- negative cases was aged
65.8 years (SD = ±2.3 years) (Table 1).
The T. vaginalis culture was positive only in 6 of 171 tis-
sue specimens. The T. vaginalis antigen in prostate tissue
was detected by immunocytochemical (ICC) staining
using purified primary monoclonal anti-Trichomonas
vaginalis antibody. TVAg assay was used to detect TV in-
fection in the prostate tissue in this study in addition to
TV-DNA test to evaluate its performance using TV-DNA
test as the standard test. TV Ag was detected in 37 of 171
specimens (21.6 %); all of which were also positive for T.
vaginalis DNA by PCR however, 5 of the PCR positive
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specimens were negative for T. vaginalis antigen (Table 2).
Using PCR for detection of T. vaginalis infection as the
standard test, statistical analysis using McNemar test for
Kappa agreement showed very good strength between the
PCR and T. vaginalis antigen test and statistically no sig-
nificant difference in their sensitivities (p: 0.25); antigen
sensitivity: 89.29 %, 95%CI = 71.77–97.73 %; antigen speci-
ficity: 100 %, 95%CI = 95.85–100 %) (Table 2). No relevant
co-infection of bacterial (syphilis, gonorrhea and chla-
mydia) and viral pathogens (herpes simplex virus and hu-
man papillomavirus) was detected in prostate tissue
screened simultaneously for T. vaginalis by PCR (data not
shown). A very limited information was available on the sex-
ual history and STIs from all the enrolled cases and the con-
trols and from their hospital records, where available. The
mean age of our study group was >65 years and only 3 BPH
cases and 5 controls admitted having multiple sexual part-
ners in the past but they claimed always practicing safe sex.
T. vaginalis antibody infection or serostatus was deter-
mined in all BPH cases and controls by detecting IgG
and IgG subtype levels against purified recombinant α-
actinin proteins from T. vaginalis. The cut off values for
seropositivity or T. vaginalis antibody infection was deter-
mined by obtaining P/N ratios and absorbance score as
described earlier in materials and methods. The cut off
value for seropositive status was determined as mean OD
value of 0.70 for the IgG. A total of 53 of 171 (31.0 %)
BPH cases and 46 of 171 (26.9 %) control cases were sero-
positive for T. vaginalis infection (p: 0.19; Table 3). In
general, T. vaginalis antibody mean absorbance values for
IgGs were not significantly different in BPH or the control
group, 0.569 vs 0.561 respectively (p:0.663; Table 3). How-
ever, a greater proportion of seroreactive BPH cases had
high IgG2 subtype absorbance score than in the control
group with the mean absorbance score of 0.202 vs 0.158
respectively (p:0.000; Table 3). Additional data on BPH
PCR and seroreactivity of BPH and control cases and their
statistical analysis is presented in the additional files. A
summary of mean OD values of IgG and IgG sub-types in
BPH and control cases is presented in Table 3.
Discussion
Despite a worldwide common and progressive nature of
benign prostate hyperplasia in older men, no association
has been observed between a causative pathogen and other
etiology so far. In this study, we investigated a causative as-
sociation of T. vaginalis in men >65 years of age with BPH
by detecting T. vaginalis DNA and antigen in the prostate
tissue of BPH cases presenting without symptoms of pros-
tatitis at a surgical outpatient clinic in Kuwait. We detected
T. vaginalis DNA and T. vaginalis antigen in 24.6 and
21.6 % in the prostate tissue of the BPH cases respectively.
Although several previous case-control studies have
observed positive associations between symptomatic
STI, gonorrhea and syphilis and prostate cancer, the in-
formation on association of asymptomatic STI is limited
and more so for BPH cases with the exception of T.
vaginalis infection that showed modest association with
BPH cases [14]. Our finding for T. vaginalis infection in
BPH cases is consistent with earlier studies that reported
a high prevalence of T. vaginalis DNA in prostate tissue
(34 %) from men who underwent TURP for BPH [14]
and the urine of patients with chronic prostatitis
(21.2 %) [17]. The detection rate of T. vaginalis infection
in men has been shown to vary according to geographical
location, presence or absence of symptoms, age, presence
or absence of T. vaginalis infection in sexual partners and
diagnostic methods [18, 19]. We used PCR assay with
BTUB primer pair which is shown to have increased sensi-
tivity and specificity [14, 19, 20]. The specificity of PCR
data was further complemented by detection of T. vagina-
lis antigen in the prostate tissue with primary monoclonal
anti-Trichomonas vaginalis antibody by immunocyto-
chemistry assay. Both TV-DNA and TV Ag assays were
used to measure TV infection. While TV-DNA test has
been used in earlier studies to detect TV infection, we also
included TV Ag assay in this study to evaluate its per-
formance in detecting TV infection in the prostate
tissue. Both these assays showed very good agree-
ment and no statistically significant difference in
their sensitivities and specificities (antigen sensitivity:
89.29, antigen specificity; 100 %; p:0.25).
Table 1 Trichomonas vaginalis infection detection status by
PCR and age of BPH patients
Diagnosis T. vaginalis positive (by PCR) T. vaginalis negative (by PCR)
N (%) Mean age ±
SD











65.6 ± 5.3 129/171
(75.4)
65.8 ± 2.3
BPH benign prostatic hyperplasia, iCaP incidental prostate cancer
Table 2 Comparative performance of T. vaginalis antigen test
by immunocytochemistry assay and PCR assay to detect T.
vaginalis DNA in the prostate tissues from BPH cases
PCR TOTAL
+ −
Ag. test + 37 0 37
− 5 129 134
TOTAL 42 129 171
Ag vs. PCR• Kappa agreement: Value = 0.93; SE = 0.04; 95 % CI = 0.84–1.0;
Strength = very good• McNemar test: p-value = 0.25, not statistically significant
difference in tests’ sensitivities• antigen sensitivity: 89.29 %, 95%CI = 71.77–
97.73 %; antigen specificity: 100 %, 95%CI = 95.85–100 %)
SE standard error, CI confidence interval
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In our study, the mean age of all registered cases was
65.6 ± 5.3 years but no information was available on the
T. vaginalis infection status of their sexual partners.
Very limited information regarding the sexual history
and STIs was available from all the enrolled subjects.
When available, their hospital records were also
screened for this information. The Kuwaiti population is
a very conservative society esp. with regards to extra-
marital sexual activities and as such, STI data registry is
very limited at the STD clinics. The mean age of our
study group was 65 years and as expected, only 3 BPH
cases and 5 controls admitted having multiple sexual
partners in the past but they claimed always practicing
safe sex. The most probable and common route of trans-
mission is sexual however, since the majority of infec-
tions in men are asymptomatic and they don’t take
treatment when their sexual partners (spouses) are diag-
nosed with T. vaginalis so the men may be carrying this
infection unnoticed. We suspect that these self-reported
rates of trichomoniasis were likely underreported the
true infection among the cases and controls because
trichomoniasis is frequently asymptomatic and infre-
quently diagnosed in men seeking STI care. In addition,
one of the selection criteria of our cases was BPH with-
out clinical symptoms of prostatitis to rule out patho-
genic and/or non-pathogenic acute infections. As such,
T. vaginalis seroreactivity status was used to assess a
history of trichomoniasis to establish a temporal rela-
tionship between trichomonal exposure and BPH, and to
detect asymptomatic infections that might otherwise not
be registered by self-report.
Recently, exposure to environmental factors such as
infectious agents, hormonal imbalances and dietary car-
cinogens were proposed to lead to injury of the prostate
and to the development of chronic inflammation how-
ever, no such hypothesis was forwarded for BPH [19]. A
relatively high detection rate of T. vaginalis DNA by
PCR and trichomonas specific antigen by ICC in the
prostate tissue of asymptomatic BPH cases in this report
provides a strong direct evidence of intraprostatic T.
vaginalis infection indicating chronic retention of this
parasite in the prostate tissue, which may be linked to
development of BPH. Recently, an in vitro evidence of
inflammatory response of prostate epithelial cells to
stimulation by T. vaginalis mediated by immune cells
and cytokines supported the role of trichomonas in
prostate hyperplasia [19].
In this study, the seropositivity for antibodies to T.
vaginalis in BPH cases (31.0 %) and in the control group
(26.9 %) was relatively higher in our study population
than some of the earlier reports (p: 0.19) [16, 21]. A
panel of five known seropositive and seronegative pooled
specimens were included with each test run to deter-
mine the cut-off points and absorbance score for T.
vaginalis infection. The differences in assay sensitivities
and demographic characteristics may account for some
of the variations in distribution of T. vaginalis seroposi-
tivity in these studies. In general, T. vaginalis antibody
mean ODs for IgGs were not significantly different in
BPH or the control group, 0.569 vs 0.561 respectively
(p:0.663). However, a greater proportion of BPH cases
had high IgG2 subtype OD values than in the control
group with the mean ODs of 0.202 vs 0.158 respectively
(p:0.000) which may be incidental and we don’t have any
explanation for its biological relevance. Furthermore, no
significant association was observed between seroreac-
tivity and T. vaginalis DNA status in the prostate tissue
(p:0.259). A number of large nested case-control studies
have observed a positive association between T. vaginalis
antibody seropositivity and prostate cancer [16, 21–23]
but very little is known on seroreactivity to T. vaginalis
in BPH cases. Recently, in a large retrospective and pro-
spective study most of the STIs did not contribute to
BPH development but a modest association of T. vagina-
lis infection with nocturia and a large prostate volume
was observed [10]. A number of reports documenting
serum antitrichomonal antibodies in male and female
patients with acute and chronic trichomoniasis [24], and
the increase in the prevalence of T. vaginalis with age
suggested the prostate to be the reservoir for T. vagina-
lis [25, 26].
Conclusions
In conclusion, we report an expected association of T.
vaginalis infection in BPH cases by detecting T. vagina-
lis DNA and antigen in 24.6 and 21.6 % respectively in
the prostate tissue of the BPH cases not presenting with
symptoms of prostatitis. The seroprevalence of T. vagi-
nalis infection was 31.0 % in BPH cases and 26.9 % in
the control subjects with no significant difference in
Table 3 T. vaginalis a-actin IgG and IgG-subtype antibody levels








49 (28.7 %) 0.19
Mean ODa
Total IgGs 0.569 0.561 0.663
Median OD
Total IgGs 0.592 0.567
Mean OD
IgG1 0.086 0.088 0.758
IgG2 0.202 0.158 0.000a
IgG3 0.159 0.153 0.374
IgG4 0.113 0.112 0.936
a optical density
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their mean absorbance values or presence of T. vaginalis
DNA in the prostate tissue. We also conclude from this
study that a large proportion of the detected trichomo-
nas infections in men were chronic, asymptomatic infec-
tions, which, without treatment, may have progressed to
the prostate tissue causing chronic prostate infection.
This would induce an inflammatory response in the nor-
mal prostate that may potentially lead to hyperprolifera-
tion of prostatic epithelial cells leading to BPH. Further
epidemiological and case-controlled studies are needed
to focus on local response to chronic asymptomatic re-
tention of T. vaginalis in prostate tissue in the develop-
ment of BPH.
Additional file
Additional file 1: Raw data and statistical analysis. All data generated or
analyzed during this study on each individual benign prostate
hyperplasia (BPH) and control case is presented. The data includes
information on the following: -Levels of IgG subtypes (OD values), -T
vaginalis-PCR positive and negative cases (OD values), -All statistical data
analyzed during this study on IgG subtypes among BPH and control
subjects. (XLSX 39 kb)
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